全文获取类型
收费全文 | 25599篇 |
免费 | 1973篇 |
国内免费 | 124篇 |
专业分类
耳鼻咽喉 | 294篇 |
儿科学 | 761篇 |
妇产科学 | 460篇 |
基础医学 | 2872篇 |
口腔科学 | 494篇 |
临床医学 | 2620篇 |
内科学 | 5618篇 |
皮肤病学 | 402篇 |
神经病学 | 2402篇 |
特种医学 | 1061篇 |
外国民族医学 | 2篇 |
外科学 | 3913篇 |
综合类 | 574篇 |
一般理论 | 26篇 |
预防医学 | 2142篇 |
眼科学 | 658篇 |
药学 | 1662篇 |
中国医学 | 35篇 |
肿瘤学 | 1700篇 |
出版年
2022年 | 202篇 |
2021年 | 448篇 |
2020年 | 266篇 |
2019年 | 421篇 |
2018年 | 469篇 |
2017年 | 349篇 |
2016年 | 338篇 |
2015年 | 461篇 |
2014年 | 624篇 |
2013年 | 969篇 |
2012年 | 1414篇 |
2011年 | 1396篇 |
2010年 | 834篇 |
2009年 | 744篇 |
2008年 | 1285篇 |
2007年 | 1418篇 |
2006年 | 1422篇 |
2005年 | 1411篇 |
2004年 | 1326篇 |
2003年 | 1249篇 |
2002年 | 1210篇 |
2001年 | 390篇 |
2000年 | 342篇 |
1999年 | 385篇 |
1998年 | 346篇 |
1997年 | 289篇 |
1996年 | 318篇 |
1995年 | 255篇 |
1994年 | 217篇 |
1993年 | 212篇 |
1992年 | 277篇 |
1991年 | 238篇 |
1990年 | 278篇 |
1989年 | 235篇 |
1988年 | 264篇 |
1987年 | 246篇 |
1986年 | 232篇 |
1985年 | 244篇 |
1984年 | 242篇 |
1983年 | 241篇 |
1982年 | 252篇 |
1981年 | 235篇 |
1980年 | 231篇 |
1979年 | 215篇 |
1978年 | 175篇 |
1977年 | 164篇 |
1976年 | 164篇 |
1975年 | 142篇 |
1974年 | 156篇 |
1973年 | 133篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
Geneticists have, for years, understood the nature of genome‐wide association studies using common genomic variants. Recently, however, focus has shifted to the analysis of rare variants. This presents potential problems for researchers, as rare variants do not always behave in the same way common variants do, sometimes rendering decades of solid intuition moot. In this paper, we present examples of the differences between common and rare variants. We show why one must be significantly more careful about the origin of rare variants, and how failing to do so can lead to highly inflated type I error. We then explain how to best avoid such concerns with careful understanding and study design. Additionally, we demonstrate that a seemingly low error rate in next‐generation sequencing can dramatically impact the false‐positive rate for rare variants. This is due to the fact that rare variants are, by definition, seen infrequently, making it hard to distinguish between errors and real variants. Compounding this problem is the fact that the proportion of errors is likely to get worse, not better, with increasing sample size. One cannot simply scale their way up in order to solve this problem. Understanding these potential pitfalls is a key step in successfully identifying true associations between rare variants and diseases. 相似文献
4.
5.
Henry Havel Gregory Finch Pamela Strode Marc Wolfgang Stephen Zale Iulian Bobe Hagop Youssoufian Matthew Peterson Maggie Liu 《The AAPS journal》2016,18(6):1373-1378
Advancing nanomedicines from concept to clinic requires integration of new science with traditional pharmaceutical development. The medical and commercial success of nanomedicines is greatly facilitated when those charged with developing nanomedicines are cognizant of the unique opportunities and technical challenges that these products present. These individuals must also be knowledgeable about the processes of clinical and product development, including regulatory considerations, to maximize the odds for successful product registration. This article outlines these topics with a goal to accelerate the combination of academic innovation with collaborative industrial scientists who understand pharmaceutical development and regulatory approval requirements—only together can they realize the full potential of nanomedicines for patients. 相似文献
6.
PNPLA3 gene polymorphism and response to lifestyle modification in patients with nonalcoholic fatty liver disease
下载免费PDF全文
![点击此处可从《Journal of gastroenterology and hepatology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
7.
8.
Implications for Practice
Breast cancer is far more curable than in the past but requires multimodality treatment. Great care must be taken to use the least leukemogenic treatment programs that do not sacrifice efficacy. Elimination of radiation and anthracycline/alkylating agent regimens will be helpful where possible, particularly in younger patients and possibly those with homologous repair deficiency (HRD). Use of colony-stimulating factors should be limited to those who truly require them for safe chemotherapy administration. Further study of a possible leukemogenic association with HRD and the various forms of colony-stimulating factors is badly needed.9.
10.